Belimumab: Anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator

Drugs in R and D

Volumn 9, Issue 3, 2008, Pages 197-202

[No Author Info available]

Author keywords

Autoimmune disorders; Belimumab, therapeutic use; Monoclonal antibodies, therapeutic use; Research and development; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB; BLYS; PLACEBO; PREDNISONE;

AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG COST; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROFIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 43649094546     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809030-00008     Document Type: Review

References (21)

1. Human Genome Sciences Inc. Human Genome Sciences Reports Results of Phase 1 Clinical Trial of Lymphostat-B(TM) in Patients with Systemic Lupus Erythematosus. Media Release: 28 Oct 2003. Available from URL: http://www.hgsi.com
2. Human Genome Sciences Inc. Human Genome Sciences Announces Phase 3 Clinical Development Program for Lympho-Stat-B(TM) in Systemic Lupus Erythematosus. Media Release: 9 Aug 2006. Available from URL: http://www.hgsi.com
3. Human Genome Sciences Inc. GlaxoSmithKline Exercises Option to LymphoStat-B(TM). Media Release: 7 Jul 2005. Available from URL: http://www.hgsi.com
4. MedImmune Inc. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune. Media Release: 29 Oct 2007. Available from URL: http://www.medimmune.com
5. Human Genome Sciences Inc. Human Genome Sciences Announces 2008 Goals and Reports Substantial Progress Toward Commercialization at JPMorgan Healthcare Conference. Media Release: 7 Jan 2008. Available from URL: http://www.hgsi.com
6. Petri M, Furie R, Ginzler E. et al. Novel combined response endpoint and systemic lupus erythematosus flare index demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy. Arthritis and Rheumatism 56 (Suppl.): 527 abstr. 1316, No. 9, Sep 2007
7. Human Genome Sciences Inc. Human Genome Sciences Reports Financial Results for Full Year and Fourth Quarter 2005. Media Release: 9 Feb 2006. Available from URL: http://www.hgsi.com
8. Cambridge Antibody Technology Group PLC. Cambridge Antibody Technology Group plc Announces Interim Results for the Six Months Ended 31 March 2006. Media Release: 22 May 2006. Available from URL: http://www.cambridgeantibody.com
9. Human Genome Sciences Inc. Human Genome Sciences Initiates Phase 2 Clinical Trial of LymphoStat-B(TM) for the Treatment of Systemic Lupus Erythematosus. Media Release: 25 Sep 2003. Available from URL: http://www.hgsi.com
10. Human Genome Sciences Inc. Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients With Systemic Lupus Erythematosus. Media Release: 6 Oct 2005. Available from URL: http://www.hgsi.com
11. Human Genome Sciences Inc. Results of Phase 1 Clinical Trial Demonstrate That LymphoStat-B(TM) Is Safe and Biologically Active in Patients with Systemic Lupus Erythematosus. Media Release: 21 Apr 2003. Available from URL: http://www.hgsi.com
12. Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphoStat-B (human monoclonal antibody to VLyS) in SLE patients. Arthritis and Rheumatism 48 (Suppl.): 377, No. 9, Sep 2003
13. Human Genome Sciences Inc. Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients with Rheumatoid Arthritis. Media Release: 6 Apr 2005. Available from URL: http://www.hgsi.com
14. Halpern WBG, Lappin P, Zanardi T. et al. Effects of lymphoS-tat-B, a BLyS antagonist, when administered intravenously to cynomolgus monkeys. Arthritis and Rheumatism 48 (Suppl.): 594, No. 9, Sep 2003
15. Stohl W, Chatham W, Weisman M, et al. Belimumab, a novel fully human monoclonal antibody to B-lymphocyte stimulator, selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis and Rheumatism 52 (Suppl.): 444 (plus oral presentation) abstr. 1160, No. 9, Sep 2005
16. Human Genome Sciences Inc. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus. Media Release: 14 Jun 2007. Available from URL: http://www.hgsi.com
17. Human Genome Sciences Inc. Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus. Media Release: 14 Nov 2006. Available from URL: http://www.hgsi.com
18. Human Genome Sciences Inc. Human Genome Sciences Reports Positive Data from Long-Term Treatment with Lympho-Stat-B(R) in Patients with Active Systemic Lupus Erytheia matosus. Media Release: 9 Nov 2007. Available from URL: http://www.hgsi.com
19. Human Genome Sciences Inc. Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus. Media Release: 22 Jun 2006. Available from URL: http://www.hgsi.com
20. Human Genome Sciences Inc. Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization. Media Release: 4 Oct 2006. Available from URL: http://www.hgsi.com
21. Stohl W, Chatham W, McKay J, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus patients. Arthritis and Rheumatism 56 (Suppl.): 210 abstr. 426, No. 9, Sep 2007